Advanced Biomed Inc. Common Stock (ADVB)

FairStock Score: 82/100 — HIGH CONVICTION

Key Financials

Strengths

• High return on equity of 80.2% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.08, providing financial flexibility
• FairStock composite score of 82/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Advanced Biomed Inc. Common Stock is a micro-cap healthcare company valued at $7 million. From a quality standpoint, Advanced shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 2.5 in the grey zone. On valuation, the stock is deeply undervalued on a P/E basis at 1.8x, with offers a 81% margin of safety vs Graham Number of $26. Growth dynamics show profit growth of 855.4%. Our composite FairStock Score of 82/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Advanced's consistent 80% ROE at just 2x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer